Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice
David Bending, Hugo De La Peña, Marc Veldhoen, Jenny M. Phillips, Catherine Uyttenhove, Brigitta Stockinger, Anne Cooke
David Bending, Hugo De La Peña, Marc Veldhoen, Jenny M. Phillips, Catherine Uyttenhove, Brigitta Stockinger, Anne Cooke
View: Text | PDF
Research Article Immunology

Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice

  • Text
  • PDF
Abstract

Th17 cells are involved in the pathogenesis of many autoimmune diseases, but it is not clear whether they play a pathogenic role in type 1 diabetes. Here we investigated whether mouse Th17 cells with specificity for an islet antigen can induce diabetes upon transfer into NOD/SCID recipient mice. Induction of diabetes in NOD/SCID mice via adoptive transfer of Th1 cells from BDC2.5 transgenic mice was prevented by treatment of the recipient mice with a neutralizing IFN-γ–specific antibody. This result suggested a major role of Th1 cells in the induction of disease in this model of type 1 diabetes. Nevertheless, transfer of highly purified Th17 cells from BDC2.5 transgenic mice caused diabetes in NOD/SCID recipients with similar rates of onset as in transfer of Th1 cells. However, treatment with neutralizing IL-17–specific antibodies did not prevent disease. Instead, the transferred Th17 cells, completely devoid of IFN-γ at the time of transfer, rapidly converted to secrete IFN-γ in the NOD/SCID recipients. Purified Th17 cells also upregulated Tbet and secreted IFN-γ upon exposure to IL-12 in vitro and in vivo in NOD/SCID recipients. These results indicate substantial plasticity of Th17 commitment toward a Th1-like profile.

Authors

David Bending, Hugo De La Peña, Marc Veldhoen, Jenny M. Phillips, Catherine Uyttenhove, Brigitta Stockinger, Anne Cooke

×

Figure 1

Th17 cells cause diabetes in NOD/SCID mice.

Options: View larger image (or click on image) Download as PowerPoint
Th17 cells cause diabetes in NOD/SCID mice.
(A) Intracellular staining f...
(A) Intracellular staining for IL-17 and IFN-γ of polarized Th17 or Th1 BDC2.5 cells was performed on day 4 of culture. Cells were transferred into NOD/SCID recipients and incidence of diabetes for Th1 (n = 5) (filled symbols) and Th17 (n = 5) (open symbols) transfer is shown. (B) Intracellular staining of CD4+Vβ4+ T cells in the PLNs on day 8 after transfer is shown. (C) Intracellular staining was performed as in A, followed by transfer into antibody-treated NOD/SCID recipients. Th17 were transferred into isotype control–treated (n = 4) (open diamonds) or anti–IFN-γ–treated (n = 5) (filled squares) hosts. Th1 were transferred into isotype-treated (n = 4) (open triangles) or anti–IFN-γ–treated (n = 5) (filled diamonds) hosts. (D) Representative FACS plots of CD4+Vβ4+ T cells in PLNs and pancreata of isotype–treated (left panels) or anti–IFN-γ–treated (right panels) hosts 10 days after transfer. Numbers indicate the percentage of cells in each quadrant.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts